[go: up one dir, main page]

PE20142295A1 - Composiciones y metodos para el tratamiento de enfermedades y trastornos hepaticos - Google Patents

Composiciones y metodos para el tratamiento de enfermedades y trastornos hepaticos

Info

Publication number
PE20142295A1
PE20142295A1 PE2014001110A PE2014001110A PE20142295A1 PE 20142295 A1 PE20142295 A1 PE 20142295A1 PE 2014001110 A PE2014001110 A PE 2014001110A PE 2014001110 A PE2014001110 A PE 2014001110A PE 20142295 A1 PE20142295 A1 PE 20142295A1
Authority
PE
Peru
Prior art keywords
disorders
compositions
treatment
methods
hepatic diseases
Prior art date
Application number
PE2014001110A
Other languages
English (en)
Inventor
Elizabeth Mckenna
Original Assignee
Elizabeth Mckenna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elizabeth Mckenna filed Critical Elizabeth Mckenna
Publication of PE20142295A1 publication Critical patent/PE20142295A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

REFERIDO A UNA COMPOSICION QUE COMPRENDE: A) UN LISADO O EXTRACTO DE PARED CELULAR A PARTIR DE UNA BACTERIA GRAM-POSITIVA LA CUAL SE SELECIONA DEL GRUPO DE BACILLUS COAGULANS, BIFIDOBACTERIUM ANIMALIS, ENTRE OTROS; B) UN PROMOTOR, QUE SE SELCCIONA DE POLI-L-LISINA, GLUCOSAMINA, ENTRE OTROS; C) UN PORTADOR OPCIONAL, QUE SE SELECCIONA DE UN AGLUTINANTE, UNA BASE DE GOMA, ENTRE OTROS; D) AGENTE DE CONTROL DE LIBERACION. DICHA COMPOSICION ES UTIL PARA TRATAR UN TRASTORNO HEPATICO.
PE2014001110A 2012-01-16 2013-01-16 Composiciones y metodos para el tratamiento de enfermedades y trastornos hepaticos PE20142295A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261586975P 2012-01-16 2012-01-16

Publications (1)

Publication Number Publication Date
PE20142295A1 true PE20142295A1 (es) 2014-12-19

Family

ID=48799623

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001110A PE20142295A1 (es) 2012-01-16 2013-01-16 Composiciones y metodos para el tratamiento de enfermedades y trastornos hepaticos

Country Status (19)

Country Link
US (4) US9713630B2 (es)
EP (1) EP2804613A4 (es)
JP (1) JP6632802B2 (es)
KR (3) KR20200106088A (es)
CN (2) CN113813294A (es)
AP (1) AP2014007804A0 (es)
AU (3) AU2013209887B2 (es)
BR (1) BR112014016389A8 (es)
CA (2) CA2860311A1 (es)
CR (1) CR20140342A (es)
EA (1) EA201491081A1 (es)
HK (1) HK1198909A1 (es)
IL (1) IL233639B (es)
NI (1) NI201400076A (es)
NZ (1) NZ625592A (es)
PE (1) PE20142295A1 (es)
PH (1) PH12014501620A1 (es)
SG (3) SG11201402650RA (es)
WO (1) WO2013109635A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6632802B2 (ja) 2012-01-16 2020-01-22 マッケンナ，エリザベス 肝疾患及び肝障害を治療するための組成物及び方法
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
JP2015535829A (ja) 2012-09-21 2015-12-17 マッケーナ、エリザベス 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用
WO2015021936A1 (en) * 2013-08-16 2015-02-19 The University Of Hong Kong Method and compositions for treating cancer using probiotics cross-reference to related application
CN107405321A (zh) * 2015-01-23 2017-11-28 坦普尔大学 短链脂肪酸在癌症预防中的应用
KR20170032815A (ko) * 2015-09-15 2017-03-23 경희대학교 산학협력단 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물
JP2018532814A (ja) * 2015-11-10 2018-11-08 マッケンナ，エリザベス 細胞の酸化還元レベルの制御
US20170143972A1 (en) * 2015-11-19 2017-05-25 Boston Scientific Neuromodulation Corporation Neuromodulation for neuroinflammation treatments with parameters controlled using biomarkers
CN107080755A (zh) * 2017-04-28 2017-08-22 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗慢性阻塞性肺疾病制剂中的应用
US11602552B2 (en) 2018-02-02 2023-03-14 Kobiolabs, Inc. Lactobacillus plantarum KBL396 strain and use thereof
RU2696773C1 (ru) * 2018-08-13 2019-08-06 Алексей Николаевич Осинцев Способ получения лекарственного препарата пептидной природы с контролируемым и последовательным высвобождением
CN110694069B (zh) * 2019-11-08 2022-02-25 重庆医科大学附属第二医院 一种防治爆发性肝炎的药物
CN110898063A (zh) * 2019-12-06 2020-03-24 湘北威尔曼制药股份有限公司 哌拉西林和舒巴坦的药物组合治疗细菌感染合并乙肝的新适应症
CN111494431B (zh) * 2020-04-28 2021-06-22 苏州大学 益生菌在制备治疗肝脏疾病制剂中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3806290A (en) 1972-07-12 1974-04-23 Warner Lambert Co Apparatus for center-filled chewing gum
US4322405A (en) 1981-04-06 1982-03-30 Laboratoires Om Societe Anonyme Method for treating rheumatoid arthritis
JPH04264034A (ja) 1991-02-18 1992-09-18 Snow Brand Milk Prod Co Ltd 生体内過酸化脂質抑制剤
IT1254210B (it) 1992-02-10 1995-09-14 Simone Claudio De Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego
US5716615A (en) 1992-02-10 1998-02-10 Renata Maria Anna Cavaliere Vesely Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
IT1283225B1 (it) * 1996-03-11 1998-04-16 Renata Maria Anna Ve Cavaliere Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle
JPH09301878A (ja) 1996-05-13 1997-11-25 Youshindou:Kk 腫瘍増殖抑制剤
JPH09301877A (ja) * 1996-05-13 1997-11-25 Youshindou:Kk 肝炎治療・予防剤
AR022986A1 (es) 1996-08-12 2002-09-04 Gist Brocades Bv Produccion y uso de composiciones que comprenden concentraciones altas de actividad de vitamina b12
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP5087758B2 (ja) 1997-03-10 2012-12-05 オタワ ホスピタル リサーチ インスティチュート アジュバントとして非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
US6281191B1 (en) * 1997-12-29 2001-08-28 Vladimir I. Slesarev Compositions and methods for treating hepatitis-C
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
JP4074006B2 (ja) 1998-06-24 2008-04-09 アサマ化成株式会社 ＩｇＥ抗体産生抑制物質の製造方法並びにそれを用いた食品
EP1178118A1 (en) 2000-08-02 2002-02-06 Dsm N.V. Isolation of microbial oils
JP2004520420A (ja) 2001-03-05 2004-07-08 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味が遮蔽された製薬学的組成物
JP3853673B2 (ja) * 2001-03-09 2006-12-06 森永乳業株式会社 Ｃ型慢性肝炎治療剤
SG177000A1 (en) 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
WO2003030613A2 (en) * 2001-10-05 2003-04-17 Intermune, Inc. Methods of treating liver fibrosis and hepatitis c virus infection
GB0203306D0 (en) 2002-02-12 2002-03-27 Norferm Da Method
CA2502960A1 (en) 2002-10-22 2004-05-06 Board Of Regents, The University Of Texas System Active specific immunotherapy of cancer metastasis
KR20050065661A (ko) 2002-11-01 2005-06-29 비로파마 인코포레이티드 벤조푸란 화합물, 조성물 및 ｃ형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법
US7078165B2 (en) * 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
WO2005027829A2 (en) 2003-09-03 2005-03-31 Intralytix, Inc. Method for vaccination of poultry by bacteriophage lysate
JP3976742B2 (ja) 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
JP2005247780A (ja) * 2004-03-05 2005-09-15 Masakazu Maruyama ウイルス性肝炎治療剤
US8182849B2 (en) * 2005-02-23 2012-05-22 Otsuka Pharmaceutical Co., Ltd. Fermented tea beverage and tea beverage
AU2006247618A1 (en) 2005-05-12 2006-11-23 Martek Biosciences Corporation Biomass hydrolysate and uses and production thereof
TW200803872A (en) 2005-07-29 2008-01-16 Suntory Ltd Compositions comprising fucoidan or a fucoidan hydrolysate and an immuno-stimulating material
ES2526879T3 (es) 2006-02-15 2015-01-16 Adiutide Pharmaceuticals Gmbh Composiciones y procedimientos para formulaciones de oligonucleótidos
EP1872792A1 (en) 2006-06-29 2008-01-02 Biotech Tools S.A. A method for the production of hydrolyzed allergen
US8304226B2 (en) 2006-08-22 2012-11-06 Carl Miller Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine
US8007783B2 (en) 2006-08-22 2011-08-30 Carl Miller Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
JP4565057B2 (ja) 2008-07-04 2010-10-20 日本ハム株式会社 イムノグロブリンａ誘導能の高い新規乳酸菌
KR20100008356A (ko) 2008-07-15 2010-01-25 한올제약주식회사 칼슘채널길항제를 포함하는 약제학적 제제
AU2008361375B2 (en) 2008-09-04 2014-05-22 Om Pharma Immunomodulatory extracts from Lactobacillus bacteria and methods of manufacturing and use thereof
US20120058962A1 (en) 2009-05-20 2012-03-08 Lingual Conseqna Pty Ltd. Buccal and/or sublingual therapeutic formulation
JP6019492B2 (ja) 2009-08-28 2016-11-02 国立大学法人 千葉大学 乳酸菌および抗原物質を含み、口腔内に投与されることを特徴とする抗アレルギー剤
FR2951377B1 (fr) * 2009-10-21 2012-06-22 Oreal Association d'un lysat de probiotique et d'un derive c-glycoside
GB201009273D0 (en) 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
JP6632802B2 (ja) 2012-01-16 2020-01-22 マッケンナ，エリザベス 肝疾患及び肝障害を治療するための組成物及び方法
JP2015535829A (ja) 2012-09-21 2015-12-17 マッケーナ、エリザベス 天然に存在するＣｐＧオリゴヌクレオチド組成物およびその治療的適用

Also Published As

Publication number Publication date
US20190290703A1 (en) 2019-09-26
NI201400076A (es) 2015-04-13
HK1198909A1 (en) 2015-06-19
PH12014501620A1 (en) 2014-10-13
US10149869B2 (en) 2018-12-11
SG10202013014RA (en) 2021-02-25
US12343361B2 (en) 2025-07-01
CN104144693A (zh) 2014-11-12
US9713630B2 (en) 2017-07-25
JP2015503628A (ja) 2015-02-02
JP6632802B2 (ja) 2020-01-22
BR112014016389A8 (pt) 2021-06-08
AP2014007804A0 (en) 2014-07-31
AU2021203147A1 (en) 2021-06-10
AU2013209887A1 (en) 2019-08-08
SG11201402650RA (en) 2014-06-27
EA201491081A1 (ru) 2016-11-30
IL233639A0 (en) 2014-08-31
BR112014016389A2 (pt) 2017-06-13
KR20200106088A (ko) 2020-09-10
EP2804613A1 (en) 2014-11-26
CA2860311A1 (en) 2013-07-25
AU2025200731A1 (en) 2025-02-20
KR20220042485A (ko) 2022-04-05
SG10201605350UA (en) 2016-08-30
NZ625592A (en) 2016-09-30
CN113813294A (zh) 2021-12-21
IL233639B (en) 2021-03-25
US11857577B2 (en) 2024-01-02
EP2804613A4 (en) 2015-12-09
CR20140342A (es) 2014-12-03
US20140030194A1 (en) 2014-01-30
WO2013109635A1 (en) 2013-07-25
CA3208225A1 (en) 2013-07-25
KR20140121818A (ko) 2014-10-16
US20170348358A1 (en) 2017-12-07
US20230372410A1 (en) 2023-11-23
AU2013209887B2 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
PE20142295A1 (es) Composiciones y metodos para el tratamiento de enfermedades y trastornos hepaticos
BR112013021509A2 (pt) composições para cuidado pessoal
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
PH12017500424B1 (en) Mir-29 mimics and uses thereof
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MY197415A (en) Functional expression of monooxygenase and methods of use
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX383245B (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
BR112017017805A2 (pt) composição
MX2009006230A (es) Agonistas sinteticos de receptores de tipo toll 9.
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
PE20170010A1 (es) Composiciones y metodos para modular la expresion del factor b del complemento
CL2012002124A1 (es) Polvo de rifaximina que comprende un tamaño de partícula entre 40 y 120 micrómetros; composiciones de liberacion controlada que contienen dicha rifaximina y su proceso de preparación, util para el tratamiento de infección intestinales bacterianas..
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
PH12014502243A1 (en) Novel bacillus subtilis
UY32214A (es) Agonistas del receptor s1p para el tratamiento de malaria cerebral
PH12019501224A1 (en) Compositions for treatment of polycystic kidney disease
CO2017002312A2 (es) Compuestos bicíclicos sustituidos
CL2018001279A1 (es) Spodoptera frugiperda resistente a vip3a.
CL2008003489A1 (es) Composicion de microcapsulas de copolimero lactico-co-glicolico (plga) o copolimero lactico co-glicolico y polietilenglicol (plga-peg) comprendiendo somatostatina o un analogo del mismo; y su uso para tratar y/o prevenir la diarrea.
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
MX2013001612A (es) Moduladores de trpv3 novedosos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal